DMD Therapy Sale: Capricor’s European Rights Sold for $35 Million
DMD therapy by Capricor is making headlines as the company finalizes a deal selling its European rights for a substantial $35 million. This transaction follows a profitable acquisition of U.S. rights by Nippon Shinyaku, signaling significant corporate interest in Duchenne muscular dystrophy treatments.
With FDA application deadlines approaching, the urgency surrounding this potential breakthrough therapy is palpable. Stakeholders are closely watching how these developments unfold, as they could forge new pathways in medical treatment for DMD.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.